



*cancers*



an Open Access Journal by MDPI

## Autophagy and Therapy Resistance in Cancers

Guest Editors:

**Prof. Dr. Raymond Lai**

Department of Laboratory  
Medicine and Pathology,  
University of Alberta, Edmonton,  
AB T6G 1Z2, Canada

**Prof. Dr. Kasper M. Rouschop**

Department of Radiotherapy,  
GROW—School for Oncology and  
Developmental Biology,  
Maastricht University Medical  
Center, 6200 MD Maastricht, The  
Netherlands

Deadline for manuscript  
submissions:

**closed (30 June 2023)**

### Message from the Guest Editors

Macroautophagy (or autophagy) is a highly evolutionarily conserved process that carries important homeostatic functions in response to various stressful stimuli. While its roles in drug resistance in cancers are far from clear, there is accumulating evidence that autophagy promotes chemoresistance in many cancer cell types and experimental models. Additionally, autophagy supports the survival of hypoxic cells, which further limits the effectiveness of chemo- and/or radiotherapy. The use of autophagy inhibitors such as chloroquine and gene silencing of specific autophagy-related genes have been shown to sensitize cancer cells to chemotherapeutic agents and radiation. One of the focuses of this issue is to further our understanding of the molecular basis underlying autophagy-related therapy resistance and to explore new ways that synergize with this process to kill cancer cells more efficiently. As recent studies have revealed the link between autophagy and stemness, it will be of interest to examine how autophagy may contribute to the high level of chemoresistance in cancer stem-like cells.



[mdpi.com/si/127733](https://mdpi.com/si/127733)

**Special** Issue



# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI